Therapeutic drug monitoring: Linezolid too?

Critical Care

Volumn 18, Issue 5, 2014, Pages

  Richards, Guy A ^a   Brink, Adrian J ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b MILPARK HOSPITAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

AREA UNDER THE CURVE; BASAL METABOLIC RATE; BURN PATIENT; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG DELIVERY SYSTEM; DRUG MONITORING; EPITHELIUM; HUMAN; HYPOALBUMINEMIA; KIDNEY CLEARANCE; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NOTE; OUTCOME ASSESSMENT; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; THERAPY EFFECT; VENTILATOR ASSOCIATED PNEUMONIA; VOLUME OF DISTRIBUTION; BLOOD; CRITICAL ILLNESS; FEMALE; INTENSIVE CARE UNIT; MALE;

ACETAMIDES; ANTI-INFECTIVE AGENTS; CRITICAL ILLNESS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; OXAZOLIDINONES;

EID: 84907062973     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0525-x     Document Type: Note

References (9)

1. Zoller M, Maier B, Hornuss C, Neugebauer C, Do¨bbeler G, Nagel D, Holdt L-M, Bruegel M, Weig T, Grabein B, Frey L, Teupser D, Vogeser M, Zander J. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care 2014, 18:R148. 10.1186/cc13984, 25011656.
2. Claus BO, Hoste EA, Colpaert K, Robays H, Decruyenaere J, De Waele JJ. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care 2013, 28:695-700. 10.1016/j.jcrc.2013.03.003, 23683557.
3. Lovering AM, Le Floch R, Hovsepian L, Stephanazzi J, Bret P, Birraux G, Vinsonneau C. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother 2009, 63:553-559. 10.1093/jac/dkn541, 19153078.
4. Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?. Antimicrob Agents Chemother 2013, 57:6165. 10.1128/AAC.00951-13, 24080664.
5. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?. Clin Infect Dis 2014, 58:1072-1083. 10.1093/cid/ciu027, 24429437.
6. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003, 42:1411-1423. 10.2165/00003088-200342150-00007, 14674791.
7. Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P, Mazzei T, De Gaudio R, Novelli A. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008, 31:122-129. 10.1016/j.ijantimicag.2007.09.009, 18055183.
8. Boselli E, Breilh D, Caillault-Sergent A, Djabarouti S, Guillaume C, Xuereb F, Bouvet L, Rimmele´ T, Saux MC, Allaouchiche B. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia. Antimicrob Chemother 2012, 67:1207-1210. 10.1093/jac/dks022.
9. Cattaneo D, Orlando G, Cozzi V, Cordier L, Baldelli S, Merli S, Fucile S, Gulisano C, Rizzardini G, Clementi E. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents 2013, 41:586-589. 10.1016/j.ijantimicag.2013.02.020, 23562639.